Products Quality Lab Reports Knowledge Calculator FAQ 💬 Get in touch
Tesamorelin / Ipamorelin Mix vial
Growth

Tesamorelin / Ipamorelin Mix.

Available Variants
17 mg

Research area: Growth

🛡️
For research purposes only. Not intended for use in humans or animals.
GH-axis research

About Tesamorelin / Ipamorelin Mix

Tesamorelin / Ipamorelin Mix is among the peptides researched in the context of the growth hormone (GH) axis. The rationale rests on mechanistic synergy: tesamorelin stimulates the GHRH receptor while ipamorelin stimulates the separate ghrelin receptor on the same somatotroph cells.

Research Application

Studied to explore whether combined GHRH-receptor and ghrelin-receptor activation produces stronger GH pulses than either peptide alone, drawing on the separately established profiles of each parent peptide.

Important to know

Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.

17 mg
Lyophilized powder
Growth
see lab reports →
Combination of two independently characterized peptides: tesamorelin, a stabilized 44-amino-acid GHRH(1-44) analog, and ipamorelin, a selective pentapeptide ghrelin-receptor (GHS-R1a) agonist.
No combination product has been reviewed for approval; the components have separate status (tesamorelin is FDA-approved as Egrifta; ipamorelin is unapproved, research-only). No clinical trials have tested the combination itself.

Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.

Research Overview

Numerous preclinical and some clinical studies exist on the GH axis, with evidentiary strength varying by substance.

Specific study references will be added for this product. For current literature, independent research (e.g. via PubMed) is recommended.

Question about Tesamorelin / Ipamorelin Mix?

We reply personally – via email or Telegram.

✉️ Email ✈️ Telegram
← Back to overview